Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Astellas Pharma Inc
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male with metastatic prostate cancer diagnosis and abstracted castration-resistant prostate cancer diagnosis
Initiated enzalutamide or abiraterone within 14 days prior to or after the metastatic castration-resistant prostate cancer diagnosis. The initiation date of enzalutamide or abiraterone will be defined as the index date.
At least 18 years old at the index date
You may not be if
Received chemotherapy, novel hormonal therapy, radium-223, olaparib/rucaparib, or immunotherapy prior to the index date
Had a prior history of other cancers
Clareo Health | A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
